Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6. The company is headquartered in Princeton, New Jersey.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-14 |
2024-03 |
0 |
0.07 |
N/A |
N/A |
2024-02-14 |
2023-12 |
0 |
-0.31 |
N/A |
N/A |
2023-12-18 |
2023-09 |
0 |
N/A |
N/A |
N/A |
2023-08-14 |
2023-06 |
0 |
-2.86 |
N/A |
N/A |
2023-05-10 |
2023-03 |
0 |
-7.47 |
N/A |
N/A |
2023-02-13 |
2022-12 |
0 |
-17.58 |
N/A |
N/A |
Date |
Name |
Relation |
Quantity |
Description |
2023-05-16 |
BHATT NAILESH |
Director |
30.73K |
Purchase |
2023-01-05 |
CINI JOHN K |
Officer |
40.27K |
Stock Award(Grant) |
2022-12-13 |
CROSS JOHN HARRY |
Chief Financial Officer |
160.68K |
Stock Award(Grant) |
2023-06-13 |
DEXTER SUSAN |
Chief Technology Officer |
33.67K |
Purchase |
2023-05-29 |
DYRNESS ALBERT D |
Director |
28.96K |
Purchase |
2022-12-08 |
GRIFFITH DONALD J. CPA |
Director |
10.30K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Sabby Management, LLC |
149.60K |
1.61M |
0.39% |
2023-06-29 |
Renaissance Technologies, LLC |
13.36K |
144.01K |
0.03% |
2023-06-29 |
Geode Capital Management, LLC |
7.70K |
83.01K |
0.02% |
2023-06-29 |
Advisory Services Network, LLC |
3.25K |
35.00K |
0.01% |
2023-06-29 |
State Street Corporation |
4.30K |
46.31K |
0.01% |
2023-06-29 |
Two Sigma Securities, LLC |
3.10K |
33.36K |
0.01% |
Split |
Date |
1 : 22 |
2023-09-01 |
1 : 14 |
2022-09-19 |
1 : 26 |
2020-04-02 |
1 : 10 |
2017-05-19 |
1 : 2 |
2012-05-25 |
2 : 1 |
2011-03-23 |